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OBJECTIVES: Patients undergoing surgery for hip frac-
ture are in the highest category of risk for postoperative
venous thromboembolism, but data on thromboprophy-
laxis in these patients were scarce. Fondaparinux, a new
synthetic selective factor Xa inhibitor proved to be more
effective than enoxaparin in preventing venous throm-
boembolism in these patients and was equally safe. We
evaluated its cost-effectiveness relative to enoxaparin 
over a period of ﬁve years post-surgery. METHODS: We
modelled the impact of fondaparinux based on 7-day 
prophylaxis on patient outcomes and costs to the UK
National Health Service (NHS). Outcomes are throm-
boembolic events (symptomatic deep vein thrombosis,
pulmonary embolism), and long term complications
(recurrences, post thrombotice syndrome), and death.
Probabilities for efﬁcacy and safety outcomes were
derived from randomised clinical trials comparing enoxa-
parin with fondaparinux, and from a review of the liter-
ature. Resource consequences were estimated from a
survey of UK hospitals and a panel of clinical experts.
Costs were estimated using mean national costs to the
NHS. RESULTS: In a hypothetical cohort of 1000
patients, fondaparinux is estimated to prevent 23 addi-
tional thromboembolic events (clinical VTE) and 6 deaths
compared to enoxaparin, with savings fully compensat-
ing added costs of prophylaxis by day 30 (break-even
point). Total savings for the cohort would be £29,000 at
5 years. These ﬁndings are robust to wide variations in
key assumptions in the model. CONCLUSIONS: Com-
pared with enoxaparin, fondaparinux is a cost-effective
and dominant strategy in prophylaxis against venous
thromboembolism following hip fracture surgery. Bene-
ﬁts of using fondaparinux begin early following surgery,
with savings increasing over time.
PCV23
ECONOMIC IMPACT OF CLOPIDOGREL IN




(PCI): A EUROPEAN OVERVIEW
Spiesser J1, Carita P1,Annemans L2, Lüscher T3, Schwarz B4,
Gabriel S5
1Sanoﬁ-Synthelabo Recherche, Bagneux, France; 2Ghent
University, HEDM, Meise, Belgium; 3University Hospital Zurich,
Zurich, Switzerland; 4University Vienna,Vienna, Austria; 5Sanoﬁ
Synthelabo, Bagneux, France
OBJECTIVE: The PCI-CURE study demonstrated that
clopidogrel compared to placebo, both groups receiving
standard therapy including ASA reduces the risk of major
cardiovascular events in patients with ACS undergoing
PCI. The purpose of this analysis was to evaluate the cost
per event avoided in Austria, Belgium, Italy, Spain, and
Switzerland. METHODS: The composite outcome used
for the cost-effectiveness analysis was the difference in
occurrences of all cardiovascular deaths, myocardial
infarctions, and strokes. Costs of hospitalization, pro-
cedures, comedications and study drug were calculated
based on resource utilization reported for all patients
undergoing PCI in the CURE study. Hospitalization 
costs were evaluated through a Diagnosis Related Group
approach in all countries. Unit costs were developed in
each country and applied to all patients of the CURE
study. Cost-effectiveness was expressed as the cost per
event avoided, in analogy with previously published eval-
uations in this area. The time horizon was that of the 
clinical trial (12 months). RESULTS: The occurrence of
the composite outcome was signiﬁcantly lower in the
clopidogrel arm compared to placebo (11.65% versus
15.17%). For every 1000 patients treated with clopido-
grel 35 additional atherothrombotic events were avoided.
The total cost of managing a patient with ACS undergo-
ing PCI ranged from €5,728 to €13,604 in the placebo
arm depending on the country. This cost was increased
by +1.2% to +4.9% in the clopidogrel arm. The cost 
of clopidogrel was partly offset by savings due to less
severe main diagnosis during hospitalizations. The incre-
mental cost per patient ranged from €166 to €390. This
resulted in a cost per cardiovascular event avoided
ranging from €4,732 to €11,065, which is better com-
pared to other interventions in this area. CONCLUSION:
Clopidogrel in patients with ACS undergoing a PCI is
cost-effective and results are very consistent across 
European countries.
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OBJECTIVES: To identify and to explain the possible dif-
ferences in resource use for the treatment of chronic heart
failure (CHF) in France (F), Germany (G), Italy (I), the
Netherlands (NL), Spain (S), and the United Kingdom
(UK). METHODS: MAHLER was a multi-centric obser-
vational (non-interventional) study on the medical man-
agement, the health care resource use and the cost of
CHF. A total of 1421 NYHA (New York Heart Associa-
tion) class II to IV patients were included and were
prospectively followed over 6 months. The frequencies of
patients using a speciﬁc resource and the mean number
of uses were computed for each country. Predictors of
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time to hospitalization for CHF were identiﬁed through
a Cox regression model. RESULTS: Mean age at inclu-
sion was 68.6 years and 31.1% of patients were female.
64% had a NYHA class II and 34.4% a NYHA class 
III while 42.4% had a history of MI. Rates of hospital-
ization for CHF ranged from 7.3% (NL) to 10.4% (S).
The Cox model indicated that a patient with the same
clinical characteristics had less chances to be hospitalized
for his CHF in the Netherlands (HR: 0.397; p = 0.003).
Individuals in the Netherlands were also more likely 
than the population as a whole to receive diuretics 
(89% vs. 79%; p = 0.0004), beta blockers (63% vs. 53%;
p < 0.0001), and spironolactone (44% vs. 28%; p <
0.0001). CONCLUSIONS: Some differences in hospital-
ization rates between EU countries were identiﬁed. They
may be related partly to differences in Health care systems
and partly to differences in use of cardiovascular 
medications.
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OBJECTIVE: To determine the 1-year cost of myocardial
infarction and stroke (ﬁrst hospitalization and follow-up)
in Hungary. METHODS: A retrospective patient follow-
up was developed in the National Health Fund Adminis-
tration (NHIFA) Database. Patients were selected by ICD
codes of myocardial infarction and stroke in the database
and were follow-up during one year (2000). All of their
resources consumption and costs reported by hospitals
and outpatient care was registered. Only resource use 
due to myocardial infarction and stroke was collected.
Costing was evaluated from the payer’s (Insurer) per-
spective. Inpatient and outpatient costs were collected.
RESULTS: The average 1-year cost of a myocardial
infarction was 374,086 HUF per patients (255,887 HUF
for acute care and 118,199 HUF for the follow-up) in
2000. The average 1-year cost of a stroke was 122,399
HUF per patient (91,027 HUF for acute care and 31,372
HUF for the follow-up). The estimated costs for year
2003 is 480 185 for the myocardial infarction and
158,059 for stroke. CONCLUSION: There is little infor-
mation about total costs of these pathologies in Hungary.
The methodology of patient follow-up was able to show
the costs paid by Insurer for patients suffering in myocar-
dial infarction and stroke. Costs evaluation allows per-
forming economic evaluation on the ﬁeld in Hungary.
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OJECTIVES: Patients undergoing hip fracture surgery are
at high risk for postoperative venous thromboembolism
(VTE) with the risk remaining elevated for several weeks.
Fondaparinux, the new synthetic selective factor Xa
inhibitor, is highly efﬁcacious and well-tolerated when
administered for 1 week. Extending prophylaxis for 4
weeks results in an additional reduction in symptomatic
VTE (relative risk reduction 89%, p = 0.02). This signif-
icant efﬁcacy beneﬁt must be weighed against the added
cost of prophylaxis for this period. This study examines
the cost-effectiveness of extending prophylaxis with fon-
daparinux from 1 to 4 weeks among patients undergoing
hip fracture surgery. METHODS: A cohort simulation
model was developed to compare the outcomes and costs
to the UK National Health Service (NHS) of extending
prophylaxis with fondaparinux for 4 weeks compared
with 1 week, up to 5 years. Probabilities for efﬁcacy and
safety outcomes were derived from randomized clinical
trials with fondaparinux, and from a literature review.
Outcomes were symptomatic VTE events (deep-vein
thrombosis, pulmonary embolism), recurrent VTE, post
thrombotic syndrome and death. Resource consequences
were estimated from a survey of UK hospitals and a panel
of clinical experts. Costs were based on mean national
costs to the NHS. Cost per life-year saved was calculated.
RESULTS: Among a cohort of 10,000 patients the use of
fondaparinux for 4 weeks compared with 1 week is esti-
mated to prevent an additional 343 symptomatic VTE 
at 3 months, of which 137 would have been fatal. The
number needed to treat to avoid an additional sympto-
matic VTE event is 30. At 5 years the incremental cost
per patient would be £108 and the cost per life year saved
£1099. CONCLUSIONS: Extending thromboprophy-
laxis with fondaparinux from 1 to 4 weeks following hip
fracture surgery appears to be a cost-effective strategy
with greater clinical beneﬁts achieved and limited addi-
tional costs incurred.
